Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients [P1.01-18]
(2018) IASLC 19th World Conference on Lung Cancer — Location: (Canada) Toronto (23.September.2018)
Files
2018_Ferrara_J_Thorac_Oncol_P101-18.pdf
Open Access - Adobe PDF
- 316.65 KB
Details
- Authors
- Abstract
- BACKGROUND : Immunosenescence is a progressive remodeling of immune functions with a multifactorial etiology (i.e. aging, chronic inflammation, cancer). Although a CD28-CD57+KLRG1+ phenotype on peripheral T-lymphocytes is a potential hallmark of immunosenescence, the characterization of such phenotype in IO-treated NSCLC patients and the correlation with clinical characteristics and benefit from immunotherapy are unknown. [...]
- Affiliations
Citations
Ferrara, R., Naigeon, M., Auclin, E., Duchemann, B., Cassard, L., Medhi, J., Boselli, L., Grivel, J., Desnoyer, A., Mezquita, L., Aboubakar Nana, F., Hendriks, L., Planchard, D., Caramella, C., Remon, J., Ngocamus, M., Nicotra, C., Besse, B., & Chaput, N. (2018). Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients [P1.01-18]. Journal of Thoracic Oncology, 13(10), S466-S467. https://doi.org/10.1016/j.jtho.2018.08.574 (Original work published 2018)